Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In


Emerging Treatments In Acute Myeloid Leukemia (AML)

Several investigational agents offer hope to patients with AML.
CME credit is no longer available for this conference.

Course Authors

Mary-Elizabeth M. Percival, M.D., M.S. and Roland B. Walter, M.D., Ph.D., M.S.

Dr. Percival is Assistant Professor of Medicine, University of Washington School of Medicine, and Assistant Member, Fred Hutchinson Cancer Research Center, and Dr. Walter is Associate Professor of Medicine, University of Washington School of Medicine, and Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Within the past 12 months, Dr. Percival has received clinical trial support from FLXBio and Dr. Walter has been a consultant to Agios Therapeutics, Amphivena Therapeutics, AstraZeneca, Covagen AG, Emergent Biosolutions, Janssen R&D, Pfizer and Seattle Genetics; received clinical trial/lab support from AbbVie, ADC Therapeutics, Amgen, Amphivena Therapeutics, Arog Pharmaceuticals, Celator, Covagen, Pharmcyclics, Seattle Genetics and Stemline Therapeutics; and has ownership interest in Amphivena Therapeutics.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Describe standard treatments for newly diagnosed AML for adults of all ages, including induction chemotherapy and allogeneic hematopoietic cell transplantation (HCT);

  • List the areas in which new treatments are needed;

  • Appreciate the importance of targeted therapies, such as small molecule inhibitors or antibodies, as an adjunct to standard AML treatments.



The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.


Please click below to accept the terms of this CME activity

Courses You Might Like


Estimated Time: 6 Hours

Unexplained Bleeding in Hospitalized Patients

While some disorders are more readily apparent than others, not all bleeding is straightforward or has a readily identifiable cause.
Authors: Meera B. Chitlur, M.D.
Estimated Time: 1 Hour

Lung Cancer Chemoprevention

Despite advances in lung cancer chemotherapy, there is a pressing need for effective lung cancer chemoprevention beyond smoking cessation.
Authors: Robert L. Keith, M.D.
Estimated Time: 1 Hour

Molecularly Targeted Therapy for Malignant Brain Tumors

Neuro−oncology is focusing on the uses of molecularly targeted agents in the adjuvant setting.
Authors: Nicole A. Shonka, M.D., and Mark R. Gilbert, M.D.
Estimated Time: 1 Hour

Anti-EGFR Therapy: Incidence, Pathology and Management of Associated Side Effects

This month, Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D., discuss

tissue including the epidermis, sweat gland apparatus and the hair follicle epithelium. , , The cutaneous reactions to EGFR inhibitors include follicular eruptions, generalized xerosis, pruritis, hyperpigmentation, panniculitis, paronychia, alopecia, trichomegaly, fine brittle hair, ocular irritation and vaginal dryness (Table 2). Current data suggest that skin eruption in patients taking
Authors: Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D.
Estimated Time: 1 Hour